tetramethylpyrazine nitrone / Magpie Pharma - LARVOL DELTA

Tetramethylpyrazine nitrone: a multifaceted neuroprotective agent in neurodegenerative disorders. (PubMed, Neurodegener Dis Manag) - "Phase I studies have established TBN's favorable oral and intravenous pharmacokinetics, effective blood - brain barrier penetration, and overall safety and tolerability in healthy volunteers. Owing to its multi-pathway mechanism, principally engaging antioxidant/mitochondrial pathways and proteostasis (autophagy/UPS), TBN represents a compelling candidate for continued clinical development, either as monotherapy or in combination with disease-specific interventions."

Journal • Review • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Metabolic Disorders • Movement Disorders • Parkinson's Disease • Targeted Protein Degradation

TETRAMETHYLPYRAZINE NITRONE IN AMYOTROPHIC LATERAL SCLEROSIS: A RANDOMIZED CLINICAL TRIAL (PACTALS 2025) - P2 | "This randomized clinical trial demonstrates that tetramethylpyrazine nitrone is safe and well-tolerated in patients with ALS. There was no difference in the primary end point across the low-dose, high-dose, and placebo groups, with significant benefits in a subgroup of younger patients with slower disease progression."

Clinical • Amyotrophic Lateral Sclerosis • CNS Disorders

Single-center, open, single-dose trial to evaluate the pharmacokinetic profile of tetramethylpyrazine nitrone (TBN) tablets in renal insufficiency and healthy subjects (ChiCTR) - P1 | N=40 | Recruiting | Sponsor: Yanbian University Affiliated Hospital (Yanbian Hospital); Guangzhou Magpie Pharmaceuticals Co., Ltd

New P1 trial • Nephrology • Renal Disease

A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of TBN (clinicaltrials.gov) - P1 | N=16 | Not yet recruiting | Sponsor: Guangzhou Magpie Pharmaceuticals Co., Ltd. | Trial completion date: Aug 2025 ➔ Aug 2026 | Trial primary completion date: Jun 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date